Cite

HARVARD Citation

    Senapati, J. et al. (n.d.). P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. HemaSphere. pp. 268-269. [Online]. 
  
Back to record